News & Media

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com.

Press Releases

All Verastem Oncology press releases are archived here.

Media Resources

Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.

 

For media interested in Verastem Oncology, please contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.

 

 

To stay updated on the latest news about Verastem Oncology, sign up for alerts.

Previous and Upcoming Events

Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.

Articles Featuring Verastem Oncology

Contact

Lisa Buffington
Corporate Communications
(781) 292-4502
media@verastem.com

Tweets by @VerastemOncolog

For those recently diagnosed with #NSCLC, @AlexSpiraMDPhD of @VCSpecialists, shares ways to work with your healthcare team to get the best care including #BiomakerTesting and exploring emerging #TargetedTherapies to determine the best treatment plan for you. #HealthyLungMonth

A trial in progress assessing $VSTM’s RAF/MEK inhibitor VS-6766 + everolimus was presented at the 2021 AACR-NCI-EORTC conference by @udai_banerji; a recommended Phase 2 dose was defined with an ongoing expansion cohort in #KRAS mutant #NSCLC. #Targets21